Champions Oncology Inc (CSBR)

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026April 9, 2026 1:40 PM
ACCESS NewswireEight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisionsHACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California.The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies. Together, the data underscore Champions Oncology's focus on helping biopharma partners better understand therapeutic response and resistance, identify actionable biomarkers, and make more informed development decisions earlier in the pipeline.Using clinically relevant, patient-derived models together with integrated molecular, functional, and phenotypic data, the studies demonstrate how translationally relevant preclinical approaches can improve prediction, reduce development risk, and strengthen the connection between tumor biology and clinical strategy."At AACR 2026, we are presenting data that directly address one of the biggest challenges in oncology R&D, making better decisions earlier," said Rob Brainin, Chief Executive Officer of Champions Oncology. "By combining clinically relevant models with deep molecular and functional data, we can help our partners understand response, anticipate resistance, and move forward with greater confidence."Champions Oncology scientists will be available throughout AACR 2026 to discuss study design, analytical approaches, and collaboration opportunities.For more information on Champions Oncology's presence at AACR 2026, including poster details and meeting opportunities, visit: https://www.championsoncology.com/meet-us-at-aacr-2026Contact InformationGavin Cooper
Vice President, Global Marketing
(518) 488-9062SOURCE: Champions Oncology, Inc.View the original press release on ACCESS NewswireOriginal: Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology StrategyMarch 30, 2026 10:55 AM
ACCESS NewswireAppointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&DHACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development.Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate deeper insights into disease biology and improve R&D outcomes. Dr. Alexander's appointment reflects the Company's continued investment in this capability and its evolution toward a more connected translational research platform."Brian brings a unique combination of clinical, scientific, and data-driven leadership experience that aligns closely with where Champions is heading," said Ronnie Morris, Chairman of the Board at Champions Oncology. "As we continue to expand our data capabilities, his perspective will help us better link tumor models with multi-omic and patient data, accelerate discovery, and support more efficient clinical development.""I'm excited to join Champions at an important point in its evolution," said Dr. Alexander. "The ability to connect well characterized tumor models with rich datasets creates a powerful opportunity to deepen our understanding of disease and enable more informed therapeutic development. I look forward to working with the team to advance this approach."Champions Oncology is building an integrated platform centered on PDX models, combining patient-derived tumors with comprehensive molecular and clinical data. This approach enhances its ability to support partners across the oncology R&D continuum, from early discovery through translational development, with a more data-informed and analytically driven strategy.To learn more about how Champions Data Services powers oncology drug discovery, visit: https://www.championsoncology.com/data-ecosystemAbout Champions OncologyChampions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative, highest-quality data through proprietary in vivo and ex vivo platforms. Utilizing its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.Contact:
Gavin Cooper - Vice President of Global Marketing
gcooper@championsoncology.com
+1 (518) 488 9062SOURCE: Champions Oncology, Inc.Related Documents:brian-alexander-champions-oncology-boardView the original press release on ACCESS NewswireOriginal: Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology Reports Revenue of $16.6 MillionMarch 12, 2026 4:01 PM
ACCESS NewswireCompany remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal yearHACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026.Third Quarter and Recent Highlights:Record study service revenue of $16.6 million, up approximately 32% year over yearTotal revenue of $16.6 million, compared to $17.0 million in the prior-year periodAdjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000The Company's third quarter reflected record service revenue driven by strong study execution and the conversion of previously booked work. As is typical in the Company's business, quarterly revenue can fluctuate depending on study timing and completion milestones. The strong third quarter reflects, in part, the conversion of backlog that had been delayed earlier in the year and may normalize somewhat in the near term before continuing to grow as bookings expand.Robert Brainin, CEO of Champions, commented, "We delivered strong operational performance in the third quarter, including another quarter of record study services revenue and our third consecutive quarter of positive adjusted EBITDA. While quarterly results can fluctuate in our business, we remain on track for annual growth and full-year positive adjusted EBIDTA while continuing to invest in our data platform and discovery therapeutics initiatives. We are also encouraged by the early momentum we are beginning to see in our data business and remain confident that our differentiated tumor bank, expanding capabilities, and growing customer engagement position Champions well for long-term growth."David Miller, CFO of Champions, added, "Study service revenue grew 32% year over year, benefiting in part from the conversion of previously booked work during the quarter. Total revenue declined modestly compared to the prior-year period due to the absence of the $4.5 million data license transaction recognized in the third quarter of last year.""Cost of sales during the quarter included more than $2 million of outsourced radiolabeling work. As this work transitions in-house over time, we expect these costs to decline and margins to improve. We also continue to invest in both our commercial organization and our data platform capabilities to expand our pipeline of opportunities and support future growth."Third Fiscal Quarter Financial ResultsTotal oncology revenue for the third quarter of fiscal 2026 was $16.6 million compared to $17.0 million for the same period last year, a decrease of 2.8%. The decline was primarily attributable to the absence of the $4.5 million data license revenue recognized in the third quarter of fiscal 2025. Excluding data, revenue increased 32% reflecting strong study execution and the conversion of bookings from earlier quarters into revenue during the third quarter.Total costs and operating expenses for the third quarter of fiscal 2026 were $16.8 million compared to $12.5 million for the third quarter of fiscal 2025, an increase of $4.3 million or 34.3%.For the third quarter of fiscal 2026, Champions reported a net loss of $279,000, including $423,000 in stock-based compensation, $341,000 in depreciation and amortization expenses, and a loss on equipment sale and disposal of $89,000 . This compares to net income of $4.5 million in the third quarter of fiscal 2025, which included $256,000 in stock-based compensation and $398,000 in depreciation and amortization expenses. Adjusted EBITDA, which is defined as net income excluding stock-based compensation, depreciation and amortization expenses, and a loss on the sale and / or disposal of lab equipment was $574,000 for the third quarter of fiscal 2026 compared to adjusted EBITDA of $5.1 million in the third quarter of fiscal 2025.Cost of oncology revenue was $8.8 million, for the three months ended January 31, 2026, an increase of$2.2 million, or 33.5%, compared to $6.6 million in the same quarter of fiscal 2025. The increase was primarily driven by higher outsourced lab service costs. As the Company transitions more of this work in-house, management expects margins to improve. Oncology services margin for the quarter was 47%, compared to 61% for three months ended January 31, 2025. The margin decline reflects outsourced radiolabeling work as well as the contribution of high-margin data revenue recognized in the prior-year period. Oncology services margin and profit are defined below in our Non-GAAP financial information discussion.Research and development expense for the three months ended January 31, 2026 was $2.3 million, an increase of $552,000 or 32.1%, compared to $1.7 million for the three months ended January 31, 2025. The increase reflected greater investment in sequencing and related activities to advance the Company's data licensing platform. Sales and marketing expense for the quarter was $2.7 million, an increase of $860,000, or 47.6%, compared to $1.8 million in the prior year period, driven primarily by higher compensation expense to support the growth of both the data and commercial businesses. General and administrative expense for the three months ended January 31, 2026 was $3.0 million, an increase of $0.6 million, or 24.1%, compared to $2.4 million for the three months ended January 31, 2025. The increase was primarily due to higher compensation expense, including stock-based compensation, and increased IT-related costs.Net cash used in operating activities was approximately $1.4 million for the three months ended January 31, 2026, primarily driven by an increase in accounts receivable and a decline in deferred revenue partially offset by an increase in accounts payable. Net cash used in financing and investing activities totaled approximately $30,000, reflecting purchases of lab and computer equipment, repayment of financing leases, and a stock options exercise.The Company ended the quarter with cash on hand of approximately $7.1 million and no debt.Year-to-date Financial ResultsTotal revenue for the nine months ending January 31, 2026 was $45.6 million, compared to $44.6 million for the same period last year, an increase of 2.2%. Total costs and operating expenses for the nine months ending January 31, 2026 were $46.2 million, compared to $38.0 million for the nine months ending January 31, 2025, an increase of $8.2 million, or 21.5%.For the nine months ending January 31, 2026, Champions reported a net loss of $508,000, including $880,000 in stock-based compensation, $1.1 million in depreciation and amortization expenses, and a loss on the sales and disposal of equipment of $110,000. This compares to net income of $6.6 million in the nine months ending January 31, 2025, which included $523,000 in stock-based compensation and $1.2 million in depreciation and amortization expenses. Excluding stock-based compensation, depreciation and amortization, and an equipment disposal and sale losses, adjusted EBITDA was $1.5 million for the nine months ending January 31, 2026, compared to $8.3 million in the nine months ending January 31, 2025.Cost of oncology services was $24.1 million for the nine months ended January 31, 2026, an increase of $3.0 million, or 14.1%, compared to $21.1 million for the same period in 2025. The increase was primarily driven from higher mice costs and outsourced lab services. Oncology services margin for current year period was 47% compared to 52.6% for the prior year period.Research and development expense for the nine months ended January 31, 2026 was $7.0 million, an increase of $2.1 million, or 43.3%, compared to $4.9 million for the same period in 2025. The increase was primarily driven by greater investment in sequencing and related costs to support the development of our data platform, as well as an increase in investment in Corellia. Sales and marketing expense for the nine months ended January 31, 2026 was $6.5 million, an increase of $1.3 million, or 24.5%, compared to the prior-year period. General and administrative expense was $8.5 million, an increase of $1.7 million, or 25.0%, compared to $6.8 million for the nine months ended January 31, 2025.Conference Call Information:The Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its third quarter financial results. To participate in the call, please call 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 957548, or provide the verbal reference "Champions Oncology".Full details of the Company's financial results will be available on or before March 16, 2026 in the Company's Form 10-Q at www.championsoncology.com.* Non-GAAP Financial InformationThis press release contains "Non-GAAP financial measures," which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP").A further explanation and reconciliation and/or calculation of these Non-GAAP financial measures is included below and in the financial tables in this release.The Company believes that the Non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company's management uses Non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results and for internal planning and forecasting purposes. Adjusted EBITDA and Adjusted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company's Adjusted EBITDA and Adjusted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate Non-GAAP financial results differently, particularly related to nonrecurring, unusual items.Adjusted EBITDAAdjusted EBITDA represents net income (loss) excluding the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.Adjusted Net Income (Loss) and Adjusted Earnings Per Share (EPS)Adjusted net income (loss) (if denoted) and adjusted EPS exclude the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.Oncology Services Profit and Oncology Services MarginOncology Services Profit is a Non-GAAP measure calculated as oncology revenue less cost of oncology revenue. Cost of oncology revenue is comprised primarily of expenses for mice, laboratory supplies, compensation, and outsourced lab services. Oncology Services margin is a Non-GAAP measure calculated as oncology services profit divided by oncology revenue.Management believes that Oncology Services Profit and Oncology Services margin are metrics which provide a clear view of direct profitability before research and development, sales and marketing, and administrative expenses are factored into our results. Management monitors these metrics closely as an indicator of pricing strategy effectiveness and resource utilization. These non-GAAP measures should not be considered in isolation or as a substitute for GAAP measures such as operating income (loss) and net income (loss). A reconciliation to the most directly comparable GAAP measure is provided in the accompanying tables.About Champions Oncology, Inc.Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions and innovative data platforms to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2025 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.Champions Oncology, Inc.
(Dollars in thousands)Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA - (Non-GAAP) (Unaudited) Three Months EndedJanuary 31, Nine Months EndedJanuary 31, 2026 2025 2026 2025 Net income (loss) - GAAP $(279) $4,495 $(508) $6,536 Less: Stock-based compensation 423 256 880 523 Depreciation and amortization 341 398 1,056 1,246 Loss on equipment sale and disposal 89 - 110 - Adjusted EBITDA - Non-GAAP $574 $5,149 $1,538 $8,305 Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited) Three Months EndedJanuary 31, Nine Months EndedJanuary 31, 2026 2025 2026 2025 EPS - basic, GAAP $(0.02) $0.33 $(0.04) $0.48 Less: Effect of stock-based compensation on EPS 0.03 0.02 0.06 0.04 Effect of depreciation and amortization on EPS 0.02 0.03 0.08 0.09 Effect of loss on equipment sale and disposal on EPS 0.01 - 0.01 - Adjusted EPS - basic, Non-GAAP $0.04 $0.38 $0.11 $0.61 Three Months EndedJanuary 31, Nine Months EndedJanuary 31, 2026 2025 2026 2025 EPS - diluted, GAAP $(0.02) $0.31 $(0.04) $0.46 Less: Effect of stock-based compensation on EPS 0.03 0.02 0.06 0.04 Effect of depreciation and amortization on EPS 0.02 0.03 0.08 0.09 Effect of loss on equipment sale and disposal on EPS 0.01 - 0.01 - Adjusted EPS - diluted, Non-GAAP $0.04 $0.36 $0.11 $0.59 Reconciliation of GAAP Income (Loss) from Operations to Oncology Services Profit and Oncology Services Margin - (Non-GAAP) (Unaudited) Three Months EndedJanuary 31, Nine Months EndedJanuary 31, 2026 2025 2026 2025 Income (loss) from operations - GAAP $(276) $4,499 $(618) $6,560 Add: Research and Development, Sales and Marketing, General and Administrative, and Loss on sale and disposal of equipment 8,001 5,923 22,118 16,911 Oncology services profit - Non-GAAP 7,725 10,422 21,500 23,471 Add: Cost of oncology revenue 8,834 6,617 24,090 21,118 Oncology revenue - GAAP $16,559 $17,039 $45,590 $44,589 Oncology services margin - Non-GAAP 47% 61% 47% 53%Unaudited Condensed Consolidated Statements of Operations (unaudited) Three Months EndedJanuary 31, Nine Months EndedJanuary 31, 2026 2025 2026 2025 Oncology revenue $16,559 $17,039 $45,590 $44,589 Cost of oncology revenue 8,834 6,617 24,090 21,118 Research and development 2,271 1,719 6,969 4,862 Sales and marketing 2,666 1,806 6,520 5,236 General and administrative 2,975 2,398 8,519 6,813 Loss on disposal of equipment 89 - 110 - Income (loss) from operations (276) 4,499 (618) 6,560 Other income, net 39 19 184 30 Income (loss) before provision for income taxes (237) 4,518 (434) 6,590 Provision for income taxes 42 23 74 54 Net income (loss) $(279) $4,495 $(508) $6,536 Net income (loss) per common share outstanding basic $(0.02) $0.33 $(0.04) $0.48 and diluted $(0.02) $0.31 $(0.04) $0.46 Weighted average common shares outstanding basic 13,886,797 13,700,627 13,805,647 13,620,686 and diluted 13,886,797 14,364,904 13,805,647 14,132,712 Condensed Consolidated Balance Sheets January 31, 2026 April 30, 2025 (unaudited) Cash and cash equivalents $7,127 $9,785 Accounts receivable, net 12,067 11,204 Other current assets 991 1,369 Total current assets 20,185 22,358 Operating lease right-of-use assets, net 4,026 5,080 Property and equipment, net 3,705 4,375 Other long term assets 196 196 Goodwill 335 335 Total assets $28,447 $32,344 Accounts payable and accrued liabilities $9,072 $6,804 Current portion of operating lease liabilities 1,529 1,471 Other current liabilities 78 135 Deferred revenue 9,998 15,443 Total current liabilities 20,677 23,853 Non-current operating lease liabilities 3,365 4,634 Other Non-current Liability 27 85 Total liabilities 24,069 28,572 Total stockholders' equity attributable to Champions Oncology, Inc. 4,283 3,772 Noncontrolling interest 95 - Total stockholders' equity 4,378 3,772 Total liabilities and stockholders' equity $28,447 $32,344 Unaudited Condensed Consolidated Statements of Cash Flows (unaudited) Nine Months EndedJanuary 31, 2026 2025 Cash flows from operating activities: Net (loss) income $(508) $6,536 Adjustments to reconcile net (loss) income to net cash (used in) provided by operations: Stock-based compensation expense 880 523 Operating lease right-of use assets 1,055 881 Depreciation and amortization expense 1,056 1,246 Gain on termination of operating lease (9) - Loss on sale and disposal of equipment 110 - Allowance and estimated credit losses (46) (320)Changes in operating assets and liabilities (5,012) (8,348)Net cash (used in) provided by operating activities (2,474) 518 Cash flows from investing activities: Proceeds from sale of equipment 23 - Purchases of property and equipment (325) (136)Net cash used in investing activities: (302) (136) Cash flows from financing activities: Proceeds from the exercise of stock options 234 314 Finance lease payments (116) (112)Net cash provided by financing activities: 118 202 Net (decrease) increase in cash (2,658) 584 Cash at beginning of period 9,785 2,618 Cash at the end of period $7,127 $3,202 SOURCE: Champions Oncology, Inc.View the original press release on ACCESS NewswireOriginal: Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026March 5, 2026 4:00 PM
ACCESS NewswireHACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the third quarter ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 957548. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 53731, or by accessing the investors section of the company's website within 72 hours.About Champions Oncology, Inc.Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.Media Inquiries:Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.comWebsite: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/SOURCE: Champions Oncology, Inc.View the original press release on ACCESS NewswireOriginal: Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

CSBR, under $8

https://seekingalpha.com/instablog/47797823-melikemsmallstocks/5296806-pktx-life-changing-science-life-changing-stock

https://championsoncology.com/news/champions-oncology-reports-record-quarterly-revenue-of-6-2-million/

I hope today was not it. Drift until December report?

CSBR watch what happenes next!

$20 in the viewfinder

SS- 200,000,000 shares authorized


outstanding
and diluted
12,618,021



excellent$$$$$

This is getting very interesting. I have said for years, with others that this would get bought out by a major player. This is finally getting noticed and solid volume. Enjoy the ride!

up 17.5

incoming $20

CSBR here we go to test 19.64

CSBR target reached...boom!!

stock of the year my friend!!!

my friend $15.68 boom

CSBR have raised the next top to be 18.50 getting ready!!

CSBR 16.32 in sight

AH $15.00!

BOOOOMMMM$$$$$$$$

$20 imminent,,,,,,

this is for real players..go back the one that will crumble to new lows!! CSBR boom!!

That's an honest mistake, or, buying a stock @ the 52 week High."

We All make mistakes, we go broke when it becomes the Trend in our Trading.

CSBR stock of the year!!

14.20 in sight!!

great thing about this company is they are not into drugs. What these guys do is very much needed for cancer therapy. They design the therapy around the patients DNA,whats works best for the patient.

Yeah, crazy. Sold and added along the way. It’s done great and more to come.

Wow. You held this long. That’s incredible. ??

First buy was at 0.07. 2007

Have you kept track of this one?!
Crazy long hold.

I Bought back higher than my sell. That’s how strong this cancer company is

$12 next month 20,,,,,,,,

may have made a mistake. This is a buy back stock...it goes a lot higher!!

CSBR ya gotta know when to hold long!!! all out!!

Boom is right friend. CSBR is a amazing little BIO company

monster:

a/s200M
o/s11M



perfect!

bingo!!!!!!!!!! trend

news

$10

CSBR ready to tackle the 10.50!! Beauty!!!

CSBR monster bio!!! Here comes 9 buckaroos!!!

been in it about a year and a half...8.06 next

I finally jumped in a year or so ago. Been a great buy for me. I started following after reading about it in Seeking Alpha. You may have seen this, but the same author just mentioned CSBR in another article recently. https://seekingalpha.com/instablog/47797823-melikemsmallstocks/5175273-knocked-horse-get-back-mantra-biotech-investor-csbr-pktx-leading-pack
Nice to see 7.00 by the way.

CSBR an amazing little bio play!!

CSBR this stock is getting the attention it deserves!!!

Been holding CSBR for 1 year now...patience paying off .Great little bio!!

Cbsr was mentioned by Seeking Alpha..

When You're Knocked Off The Horse…Get Back On! The Mantra Of A Biotech Investor…A Look Back On The Last 12 Months

Oct. 18, 2017 1:36 AM

When You're Knocked Off the Horse! Get Back On!

The Mantra of a Biotech Investor...A Look Back on the Last 12 Months

10-18-2017

I realize it's been nearly six months since my last update. My absence has not been due to lack of activity in my biotech picks.  It's been 1 year since my first "Knocked Off the Horse" article. I'm taking the one-year anniversary as an   opportunity to see how the last year treated my stable.  The performance of a couple of my thoroughbreds had me cashing in at the ticket window and a couple of nags needed to be sent out to pasture.  I'll provide a brief update on the last few months and do my best at looking forward.

First, the original 5 stocks that were written about in October 2016

CSBR, Champions Oncology - October 2016 pps - $1.67, October 2017 pps $3.31.   Yep, we got a double out of this one and the opportunity for a little trading along the way. This company is starting to mature into a real biotech.  If you've not done your research on this one, then do it now. It is still underfollowed and I believe still has plenty of opportunity ahead of it.  CSBR is still solidly in my stable.



PKTX, ProtoKinetix - October 2016 pps - .07, October 2017 pps - .07. Don't be fooled by the price being the same in now as it was in October 2016. This company has made far greater strides than what I had even imagined.  The company began its first human trials this year and the stock got as high as $.15 on the news.  I would anticipate data from these trials to begin coming out early in 2018.  The trials that are currently underway are for Diabetes, that in and of itself is enough for me to own the stock,  but the company put press out on 10.17.2017 and informed us that they will also be using their molecule for Kidney Ischemia, Normothermic Liver Perfusion, Retinal Cell Replacement and Monocional antibody production.  This company is no one trick pony!  The stock doesn't get the attention it should, this is in large part due to the fact it is trading at $.07, many biotech investors don't take a penny stock too seriously.  A little due diligence shows that this company was resurrected from the dead by current management and now has an entirely clean cap table with no debt whatsoever and as evidenced by the recent press, they're really getting things done.  It's not often I get this fired up about a penny stock biotech, but PKTX is a penny stock in price only.  The cap table and technology are deserving of a market cap far greater than what the market is currently giving it.  Once they begin to release study data the market will realize this is Secretariat and not some also ran. I'm loading up on this one while she's still priced like a longshot.

There was a 1-12 RS back in 2015.
Good to see positive news from them this month.

I had some at .05 too...

Did they do a small Reverse split or is this just up from there. Way to hold on!

Same here. Back in 2007 I believe, single digit share price. Been adding along the way. GLTA!

A company with real earnings equals share value. : ) I've been in this one since it was .05 cents a share and a start up shell company. I knew it was a winner then and still believe it to be.